A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype
• At least 12 years of age
• A minimum weight of 40kg
• A medical history of at least 1 year that meets the diagnosis of asthma;
• Current treatment with medium- or high- doses of ICS for at least 6 months and using steadily at least 3 months
• Current treatment with an additional controller medication, besides ICS, for at least 3 months and using steadily at least 1 month
• Absolute count of blood eosinophils suggests eosinophilic asthma
• During the screening period and baseline, pre- BD FEV1% \< 80%
• During the screening period and baseline, ACQ-6 score indicates asthma poor control
• History of severe asthma exacerbation within the past 12 months prior to screening
⁃ Good compliance with eDiary completion
⁃ Take efficient contraceptive measures
⁃ Voluntarily sign the informed consent form to participate in this study